Vericel Corp (VCEL) Stock Price & Analysis
Vericel Corp (VCEL) rose 3.52% to USD 37.03 as of June 10, 2026 at 09:05 UTC, according to Nexqual real-time market data.
VCEL last closed at USD 35.77; the session ranged USD 36.43–37.71 on volume of 617,182 shares. Market capitalization is $1.89B, with a 52-week range of USD 28.95–45.97 (NGM). Source: Nexqual, June 10, 2026 at 09:05 UTC.
Key Statistics (as of June 10, 2026 at 09:05 UTC)
| Price | USD 37.03 |
|---|---|
| Change | ▲ 3.52% (up) |
| Previous Close | USD 35.77 |
| Open | USD 36.67 |
| Day Range | USD 36.43 – 37.71 |
| 52-Week Range | USD 28.95 – 45.97 |
| Volume | 617,182 shares |
| Market Cap | $1.89B |
| Exchange | NGM |
Technical Analysis (VCEL)
Nexqual's technical model rates VCEL "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 09:05 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.59 (neutral) |
| vs SMA50 | Above (USD 34.34) |
| MACD | 0.25 (positive) |
Analyst Ratings (VCEL)
Wall Street analysts rate VCEL "None" based on 7 analysts, with a mean price target of USD 55.43 (range USD 42–70), per Nexqual as of June 10, 2026 at 09:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 55.43 |
| High Target | USD 70 |
| Low Target | USD 42 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (VCEL)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.04 |
| Revenue Estimate | $72.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.12 vs est -0.16 ▲ beat |
| 2025-12-31 | USD 0.45 vs est 0.38 ▲ beat |
| 2025-09-30 | USD 0.1 vs est -0.01 ▲ beat |
| 2025-06-30 | USD -0.01 vs est -0.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 09:05 UTC.
Financials & Fundamentals (VCEL)
| Total Revenue | $292.09M |
|---|---|
| Revenue Growth (YoY) | +30.10% |
| Gross Margin | +74.84% |
| Operating Margin | -11.79% |
| Profit Margin | +7.35% |
| ROE | +6.59% |
| Debt / Equity | 26.68 |
| Current Ratio | 5.18 |
| Total Cash | $145.34M |
| Total Debt | $95.04M |
| Free Cash Flow | $42.37M |
Source: Nexqual, June 10, 2026 at 09:05 UTC.
Financial Health Score (VCEL)
Nexqual rates Vericel Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 09:05 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -12% |
| Balance Sheet | Strong — $145M cash vs $95M debt, net cash position |
| Cash Flow | Strong — FCF $42M, 15% margin |
| Efficiency | Mixed — ROE 7%, ROA 2.2% |
Ownership (VCEL)
| Insider Ownership | +1.20% |
|---|---|
| Institutional Ownership | +111.21% |
| Shares Outstanding | 51.07M |
| Float | 50.43M |
| Short % of Float | +12.81% |
Source: Nexqual, June 10, 2026 at 09:05 UTC.
Leadership (VCEL)
Vericel Corp is led by Dominick C. Colangelo (age 61), CEO, President & Director, per Nexqual as of June 10, 2026 at 09:05 UTC.
| CEO, President & Director | Dominick C. Colangelo (age 61) |
|---|---|
| CFO & Treasurer | Joseph Anthony Mara (age 49) |
| Chief Operating Officer | Michael Halpin (age 63) |
| Vice President of Finance & Investor Relations | Eric Burns |
| Chief Marketing Officer | Roland DeAngelis |
Major Backers & Investors (VCEL)
Notable institutional backers of Vericel Corp include Soleus Capital Management, L.P., Conestoga Capital Advisors, LLC, William Blair Investment Management, LLC, according to Nexqual as of June 10, 2026 at 09:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Soleus Capital Management, L.P. | 4.99% |
| Conestoga Capital Advisors, LLC | 4.82% |
| William Blair Investment Management, LLC | 3.59% |
| BNP Paribas Asset Management Holding S.A. | 3.38% |
| Geneva Capital Management LLC | 3.22% |
| GW&K Investment Management, LLC | 3.17% |
| Conestoga Funds-Conestoga Small Cap Fund | 3.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.57% |
| Vanguard Group | 8.63% |
| State Street | 8.59% |
Source: Nexqual, June 10, 2026 at 09:05 UTC.
From Vericel Corp's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
- Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XNCR | Xencor, Inc. | USD 11.89 | ▲ 1.02% |
| VCYT | Veracyte, Inc. | USD 49.24 | ▲ 1.05% |
| PTCT | PTC Therapeutics, Inc. | USD 73.68 | ▲ 3.82% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 17.69 | ▲ 2.02% |
| RGNX | REGENXBIO Inc. | USD 6.34 | ▲ 4.28% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:05 UTC. This page is informational and not investment advice.